The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*
Abstract
IN 1896, George Beatson demonstrated that the removal of the ovaries from premenopausal women with metastatic breast cancer could, in some cases, cause regression of the disease and improve the prognosis of the patient (1). However, by 1900 Stanley Boyd had established that only one in three patients would obtain improvement for about 1 yr (2). Despite this disappointment, a link was established between an ovarian factor and the growth of some breast cancers. This observation was to become the foundation of modern clinical practice and the rationale for the use of antiestrogens to treat breast cancer (3, 4). At the turn of the century, studies were being conducted in the laboratory to complement the clinical effort. Inbred strains of mice were being established for medical research, and it was found that certain strains of mice developed a high incidence of mammary tumors. Lathrop and Loeb (5) reported that an early ovariectomy could prevent the spontaneous development of tumors but it was not until Allen and Doisey (6) identified “estrus stimulating principle” that ovarian hormones could be linked to the development of breast cancer. By 1936, Professor Antoine Lacassagne, again working with high-incidence strains of mice, suggested that if breast cancer was caused by a special hereditary sensitivity to estrogen, then the disease could be prevented by developing a therapeutic antagonist to estrogen action in the breast (7). However, there were no therapeutic antagonists of estrogen at that time, nor was there a target to design drug molecules. Nevertheless, exciting developments in the discovery of nonsteroidal estrogens would establish the structural basis of carrier molecules, which resulted in the design of the two drugs, tamoxifen and raloxifene (Fig. 1), both originally described as antiestrogens and used today in a clinical trial to prevent breast cancer in high-risk women (see Section IX).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932
Cited by
The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling
Hall, J. M., Couse, J. F., & Korach, K. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100029200 · Cited by 1,208
TLR7 Ligands Induce Higher IFN-α Production in Females
Berghöfer, B., Frommer, T., Haley, G., Fink, L., Bein, G., & Hackstein, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2088 · Cited by 480
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
Self-citationAlbanito, L., Madeo, A., Lappano, R., Vivacqua, A., Rago, V., Carpino, A., Oprea, T. I., Prossnitz, E. R., Musti, A. M., Andò, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2909 · Cited by 399
Chemoprevention: an essential approach to controlling cancer
Sporn, M. B., & Suh, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc844 · Cited by 379
Estrogen receptor β acts as a dominant regulator of estrogen signaling
Pettersson, K., Delaunay, F., & Gustafsson, J.-Å. (2000) · Oncogene · doi:10.1038/sj.onc.1203828 · Cited by 362
Soy Isoflavones—Benefits and Risks from Nature’s Selective Estrogen Receptor Modulators (SERMs)
Setchell, K. D. R. (2001) · Journal of the American College of Nutrition · doi:10.1080/07315724.2001.10719168 · Cited by 354
Vivacqua, A., Bonofiglio, D., Recchia, A. G., Musti, A. M., Picard, D., Andò, S., & Maggiolini, M. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0280 · Cited by 341
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Kryczek, I., Wei, S., Keller, E., Liu, R., & Zou, W. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00406.2006 · Cited by 329
Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting
Hall, J. M. (2005) · Molecular Interventions · doi:10.1124/mi.5.6.7 · Cited by 295
Hall, J. M., & Korach, K. S. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0438 · Cited by 293
Ju, Y. H., Allred, K. F., Allred, C. D., & Helferich, W. G. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi370 · Cited by 129
Lu, Y., & Liu, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00913 · Cited by 119
Walf, A. A., & Frye, C. A. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833a5cb0 · Cited by 34
Metadata
- Authors
- Jordan, V. C., & Morrow, M.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1999-06-01
- Volume
- 20
- Issue
- 3
- Pages
- 253-278
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2133249365
- Cited by
- 258
- References
- 200
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.